HHMI, Boston Children's Hospital, Boston, MA 02115.
Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115.
Proc Natl Acad Sci U S A. 2023 Jan 3;120(1):e2217883120. doi: 10.1073/pnas.2217883120. Epub 2022 Dec 27.
Antibody heavy chain (HC) and light chain (LC) variable region exons are assembled by V(D)J recombination. V(D)J junctional regions encode complementarity-determining-region 3 (CDR3), an antigen-contact region immensely diversified through nontemplated nucleotide additions ("N-regions") by terminal deoxynucleotidyl transferase (TdT). HIV-1 vaccine strategies seek to elicit human HIV-1 broadly neutralizing antibodies (bnAbs), such as the potent CD4-binding site VRC01-class bnAbs. Mice with primary B cells that express receptors (BCRs) representing bnAb precursors are used as vaccination models. VRC01-class bnAbs uniformly use human HC V1-2 and commonly use human LCs Vκ3-20 or Vκ1-33 associated with an exceptionally short 5-amino-acid (5-aa) CDR3. Prior VRC01-class models had nonphysiological precursor levels and/or limited precursor diversity. Here, we describe VRC01-class rearranging mice that generate more physiological primary VRC01-class BCR repertoires via rearrangement of V1-2, as well as Vκ1-33 and/or Vκ3-20 in association with diverse CDR3s. Human-like TdT expression in mouse precursor B cells increased LC CDR3 length and diversity and also promoted the generation of shorter LC CDR3s via N-region suppression of dominant microhomology-mediated Vκ-to-Jκ joins. Priming immunization with eOD-GT8 60mer, which strongly engages VRC01 precursors, induced robust VRC01-class germinal center B cell responses. Vκ3-20-based responses were enhanced by N-region addition, which generates Vκ3-20-to-Jκ junctional sequence combinations that encode VRC01-class 5-aa CDR3s with a critical E residue. VRC01-class-rearranging models should facilitate further evaluation of VRC01-class prime and boost immunogens. These new VRC01-class mouse models establish a prototype for the generation of vaccine-testing mouse models for other HIV-1 bnAb lineages that employ different HC or LC Vs.
抗体重链 (HC) 和轻链 (LC) 可变区通过 V(D)J 重组进行组装。V(D)J 连接区编码互补决定区 3 (CDR3),通过末端脱氧核苷酸转移酶 (TdT) 的非模板核苷酸添加 ("N 区"),极大地多样化了抗原结合区。HIV-1 疫苗策略旨在引发人类 HIV-1 广泛中和抗体 (bnAb),如强效的 CD4 结合位点 VRC01 类 bnAb。具有代表 bnAb 前体的受体 (BCR) 的原发性 B 细胞的小鼠被用作疫苗接种模型。VRC01 类 bnAb 普遍使用人类 HC V1-2,并且通常使用人类 LC Vκ3-20 或 Vκ1-33,与异常短的 5-氨基酸 (5-aa) CDR3 相关。先前的 VRC01 类模型具有非生理前体水平和/或有限的前体多样性。在这里,我们描述了 VRC01 类重排小鼠,通过 V1-2 的重排,以及与多样化的 CDR3 相关的 Vκ1-33 和/或 Vκ3-20,产生更具生理意义的原发性 VRC01 类 BCR 库。在小鼠前体 B 细胞中表达类似人类的 TdT 增加了 LC CDR3 的长度和多样性,并通过抑制显性微同源介导的 Vκ 到 Jκ 连接来促进较短的 LC CDR3 的产生。用 eOD-GT8 60mer 进行初始免疫接种,该抗原强烈结合 VRC01 前体,诱导强烈的 VRC01 类生发中心 B 细胞反应。通过 N 区添加增强了基于 Vκ3-20 的反应,该添加产生了 Vκ3-20 到 Jκ 连接的序列组合,编码具有关键 E 残基的 VRC01 类 5-aa CDR3。VRC01 类重排模型应有助于进一步评估 VRC01 类的初始和加强免疫原。这些新的 VRC01 类小鼠模型为其他 HIV-1 bnAb 谱系的疫苗测试小鼠模型的生成建立了一个原型,这些谱系采用不同的 HC 或 LC Vs。